Table 2 Procedural details and tumor responses of the HCC patients treated by cTACE with CBCT assistance (CBCT-cTACE) and patients treated by cTACE with DSA alone (DSA-cTACE)
CBCT-cTACE (n = 196) | DSA-cTACE (n = 141) | p value | |
|---|---|---|---|
Lipiodol, ml, mean (range) | 7.5 ± 3.4 (2‒16) | 7.8 ± 3.3 (2‒16) | 0.068 |
Doxorubicin dose, mg, mean (range) | 21.6 ± 10.6 (5‒50) | 33.6 ± 17.1 (5‒50) | < 0.001* |
Number of treated hepatic segments | |||
1 | 107 (54) | 76 (54) | 0.150 |
2 | 68 (35) | 59 (42) | |
3 | 16 (8) | 5 (3) | |
4 | 5 (3) | 1 (1) | |
Number of cine acquisitions, mean (range) | 4.6 (1‒14) | 5.1 (2‒17) | 0.017* |
Number of CBCT acquisitions, mean (range) | 3.4 (1‒11) | ||
Fluoroscopic time, mins, mean (range) | 16.3 (4.1‒60.4) | 12.4 (3.3‒54.4) | < 0.001* |
Post embolization syndrome (%) | |||
Yes | 19 (10) | 15 (11) | 0.920 |
No | 177 (90) | 126 (89) | |
Tumor responsea | |||
CR | 131 (67) | 31 (22) | < 0.001* |
PR | 55 (28) | 67 (48) | |
SD | 7 (4) | 13 (9) | |
PD | 3 (1) | 30 (21) | |
Additional cTACE, times, mean (range) | 2.7 (1‒10) | 3.0 (1‒14) | 0.400 |